跳至主要内容
临床试验/NCT05230771
NCT05230771尚未招募3 期

Clinical Outcome of Palliative Surgery After Translational Therapy Versus Maintenance Chemotherapy for Metastatic Gastric Cancer: a Single Center Randomized Controlled Trial

Fujian Medical University0 个研究点目标入组 120 人开始时间: 2022年4月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
120
主要终点
2-year overall survival rate

研究概览

简要总结

This single-center, prospective study was conducted to investigate the efficacy and safety of palliative surgery after translational therapy in the treatment of metastatic gastric cancer. The primary endpoint was 2-year overall survival (OS) rate. Secondary endpoints were median OS, progression-free survival (PFS), 1-year OS, adverse events (AE), severe AE, the quality of life (QOL) and treatment cost.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age from 18 to 75 years
  • Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically
  • CT/MRI, PET-CT, or laparoscopic exploration should be performed before surgery to confirm the diagnosis of distant metastasis
  • Performance status of 0 or 1 on Eastern Cooperative Oncology Group scale (ECOG)
  • Estimated survival time was over 3 months
  • The major organs are functioning normally and meet the following criteria:
  • (1) Blood routine examination should meet the requirements (no blood transfusion within 14 days):
  • WBC≥3×109/L
  • ANC≥1.5×109/L,
  • PLT≥100×109/L; (2)Biochemical tests must meet the following criteria:
  • BIL <1.5×upper limit of normal (ULN),
  • ALT and AST<2.5ULN,GPT≤1.5×ULN;
  • Cr≤1ULN,Ccr >60ml/min
  • Fertile women must have taken a pregnancy test (serum) within 7 days prior to enrollment with negative results and be willing to use an appropriate method of contraception during the trial period and 8 weeks after the last trial drug; For men, they should be surgically sterilized or agree to use the appropriate method of contraception during the trial period and 8 weeks after the last administration of the trial drug
  • Did not participate in other clinical studies before and during treatment
  • Subjects voluntarily joined the study and signed informed consent with good compliance and follow-up

排除标准

  • History of other malignant disease within past five years
  • History of immunodeficiency, including HIV positive, or other acquired congenital immunodeficiency disease, or a history of organ transplantation and allogeneic bone marrow transplantation
  • Accompanied by serious heart, lung, liver and kidney diseases, neuropsychiatric disorders, jaundice or associated severe infection
  • Women during pregnancy or breast-feeding
  • Subjects had poorly controlled cardiovascular clinical symptoms or diseases, including but not limited to:
  • NYHA class II or more serious heart failure
  • unstable angina pectoris
  • myocardial infarction within 1 year
  • clinically significant ventricular or ventricular arrhythmias that were poorly controlled without or despite clinical intervention

研究组 & 干预措施

Palliative surgery after translational therapy

Experimental

After randomization, patients received palliative surgery after translational therapy

干预措施: Palliative surgery after translational therapy (Combination Product)

Chemotherapy alone

Active Comparator

After randomization, patients received chemotherapy alone

干预措施: Chemotheraoy along (Drug)

结局指标

主要结局

2-year overall survival rate

时间窗: 2 year

Survival rate of patients in the group from the date of enrollment to 2 years after enrollment

次要结局

未报告次要终点

研究者

发起方
Fujian Medical University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Chang-Ming Huang, Prof.

chief physician

Fujian Medical University

相似试验